Evidence map›Paper›PMID 32479254›Full record

ArticleTurkish journal of urology2020

The role of COL6A1and PD-1 expressions in renal cell carcinoma.

Yasemin Yuyucu Karabulut, Emre Çağatay Köse, Murat Bozlu, Ferah Tuncel, Gül Emek Yüksek, Demet Etit, Havva Serap Toru, Bahar Akkaya, Zeliha Esin Çelik, Meltem Öznur and 2 more

Open access · greenAbstract read
In one paragraph

Article in Turkish journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Most CommonCancers · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Yasemin Yuyucu KarabulutDepartment of Medical Pathology, Mersin University School of Medicine, Mersin, Turkey.ORCID https://orcid.org/0000-0001-6619-6868
Emre Çağatay KöseDepartment of Medical Pathology, Mersin University School of Medicine, Mersin, Turkey.ORCID https://orcid.org/0000-0002-6903-9064
Murat BozluDepartment of Urology, Mersin University Medical Faculty.ORCID https://orcid.org/0000-0002-8624-0149
Ferah TuncelDepartment of Medical Pathology, Mersin University School of Medicine, Mersin, Turkey.ORCID https://orcid.org/0000-0001-6506-9461
Gül Emek YüksekMedical Pathology Laboratory, Mardin State Hospital, Mardin, Turkey.ORCID https://orcid.org/0000-0003-2938-7512
Demet EtitDepartment of Medical Pathology, İzmir Katip Çelebi University School of Medicine, İzmir, Turkey.ORCID https://orcid.org/0000-0002-6282-0173
Havva Serap ToruDepartment of Medical Pathology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID https://orcid.org/0000-0002-4438-0434
Bahar AkkayaDepartment of Medical Pathology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID https://orcid.org/0000-0001-8054-294X
Zeliha Esin ÇelikDepartment of Medical Pathology, Selçuk University School of Medicine, Konya, Turkey.ORCID https://orcid.org/0000-0002-3220-7845
Meltem ÖznurDepartment of Medical Pathology, Namık Kemal University School of Medicine, Tekirdağ, Turkey.ORCID https://orcid.org/0000-0002-6396-3168
Gülhan Örekici TemelDepartment of Biostatistics, Mersin University School of Medicine, Mersin, Turkey.ORCID https://orcid.org/0000-0002-2835-6979
Erdem AkbayDepartment of Urology, Mersin University Medical Faculty.ORCID https://orcid.org/0000-0001-7669-414X
Mersin Üniversitesi · TRAkdeniz University · TRIzmir Kâtip Çelebi University · TRMardin Artuklu University · TRSelçuk University · TRTekirdağ Namık Kemal University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe COL6A1 is a gene encoding the alpha 1 polypeptide subunit of collagen 6 (COL6A1), an extracellular matrix protein subunit. Programmed cell death receptor-1 (PD-1) and its ligand, programmed cell death receptor ligand-1 (PD-L1) have been shown to have a prognostic significance in clear cell renal cell carcinomas (RCCs). In this study, we evaluated the expressions of COL6A1 and PD-1 in four different RCC subtypes. MATERIALS AND

methodsA total of 161 radical nephrectomy and nephron-sparing surgery cases with RCCs from five different health care centers were included in this study. Clinical data of the cases were taken from electronic records of the institutions. The pathological data were collected by an expert uropathologist and re-evaluated with slides obtained from paraffin blocks of the cases. The correlation of COL6A1 and PD-1 expression with sex, age, tumor type, lymphovascular invasion (LVI), World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade, and tumor stage (pT) was analyzed with the Pearson chi-squared test.

resultsPatients with sarcomatoid RCC and clear cell RCC had significantly higher COL6A1 scores and intensities than in other types of RCC (p=0.004 and p=0.002, respectively). WHO/ISUP grade and, COL6A1 and PD-1 staining scores also showed positive correlation (r=0.230, p=0.004 and r=0.277, p=0.001, respectively for COL6A1 and r=0.191, p=0.018 and r=0.166, p=0.041, respectively for PD-1). The staining scores and intensities of COL6A1 and PD-1 were not different between the patients with positive and negative LVI (p>0.05).

conclusionIn high-grade RCCs, we found the relationship between immunohistochemical staining scores of COL6A1 and PD-1 proteins and clinical, demographic, and histopathological parameters. Our results proved that COL6A1 and PD-1 are really promising proteins as prognostic parameters and for targeted immunotherapy.

Identifiers

PMID32479254
PMCPMC7360155
OpenAlexW3030522446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.